All stock lists
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$10.64+$0.02 (+0.19%)
Market cap
$898M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 23, 2016
Website
Insider Score
82/ 100
CRVS Insider Score
Bullish4 qualifying trades · 1 insider · $50.48K bought in the last 90 days
Financial Health Score
Fair
From CRVS’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$64.3M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $632K
- Cash
- $15.0M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $206.3M
- Current liabilities
- $15.4M
- Current ratio
- 13.38
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$47.2M
- Free cash flow
- -$47.9M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 92.5M
- Share growth (1y)
- 11.7%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CRVS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $26.00 K | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$26.00 K | $0.00 | $0.00 |
| SG&A Expense | $3.58 M | $3.33 M | $3.70 M | $2.28 M | $2.12 M | $2.39 M |
| R&D Expense | $17.78 M | $15.96 M | $11.18 M | $9.94 M | $8.45 M | $7.87 M |
| Operating Expenses | $21.36 M | $19.30 M | $14.88 M | $12.19 M | $10.57 M | $10.26 M |
| Operating Income | -$21.36 M | -$19.30 M | -$14.88 M | -$12.22 M | -$10.57 M | -$10.26 M |
| Pretax Income | -$19.45 M | -$17.25 M | -$13.09 M | -$12.32 M | -$10.16 M | -$8.00 M |
| Tax Provision | $0.00 | $709.00 K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$20.34 M | -$17.96 M | -$13.69 M | -$12.32 M | -$10.16 M | -$8.00 M |
| EPS (Basic) | -$0.22 | -$0.19 | -$0.15 | -$0.18 | -$0.12 | -$0.10 |
| EPS (Diluted) | -$0.22 | -$0.19 | -$0.15 | -$0.18 | -$0.12 | -$0.10 |
| Shares Outstanding | 92.49 M | 92.37 M | 90.00 M | 78.96 M | 82.84 M | 77.77 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.